Half of all the 60,000 new cases of cervical cancer diagnosed in Europe this year will prove to be incurable and result in the patient’s death, and a similar percentage of the hundreds of thousands of women diagnosed worldwide will also die.
To make any impact on these statistics, medical researchers will need access to huge amounts of data on cervical cancer victims, the sort of data collected and analysed in what medical professionals call Association Studies.
Thanks to the work of the 2008 Nobel Prize-winning scientist, Harald zur Hausen, we know that cervical cancer is caused by the human papilloma virus (HPV). But not every woman infected with the virus develops the disease, while some of those who do develop it respond to treatment, and others do not. There is also the complication that there are many different variants of HPV, and not all of them cause cancer.
To try and understand these discrepancies in different patients, and what the root causes are, it is necessary to examine as much information as possible about as many patients as possible to try and identify common factors. Association Studies do this by studying clinical data from hospital tests, lifestyle data such as eating, smoking and sexual habits and genetic data. They also compare the data with that from healthy patients not infected by the virus.
Forging links between hospitals
Until now, these tests have generally been undertaken at individual clinics and medical centres where researchers only had access to data concerning tens or perhaps hundreds of patients. The EU-funded ASSIST project was set up to forge technological links between leading medical centres specialising in the diagnosis and treatment of cervical cancer, to allow them to share data and thus create a much larger data repository.
Says project coordinator Professor Pericles Mitkas of the Centre for Research and Technology – Hellas, Informatics and Telematics Institute, Thessaloniki: “What we are trying to do is to allow medical researchers working in specialist hospitals and medical centres to use each others’ data, and combine the data into a bigger pool to work with.”
While this may sound logical and easy, in practise it is not. “The problem is, each hospital uses different formats, different rules for storing data, even for exactly the same tests. Even within hospitals, each doctor might have his or her own way of doing things,” says Mitkas.
The challenge is primarily an IT one, but it requires doctors from various disciplines – researchers, microbiologists and geneticists at the different centres – to agree to adopt common practices for the system to work.
Agreeing on a common terminology
“Perhaps the greatest achievement of the project to date has been to get medical doctors, molecular biologists and computer scientists sitting around a table and talking to each other, and finally understanding each other’s technical language,” says Mitkas.
There are three hospitals involved in the initial stage of the project, from Greece, Germany and Belgium. Mitkas says it was also an achievement to get the doctors from these institutions to agree to “common terminology, common ground, and a common view on how to represent data and access it.”
With these agreements in place, the team developed a prototype software platform which ensures researchers get data reported back to them in a similar format and in the exact way in which it was requested. “We do this by semantic representation, which means we assign an interpretation to each value to help the computer understand what each value refers to,” Mitkas explains.
“We also facilitate interpretation of subjective values like ‘high risk’ and ‘low risk’, ‘serious cases’ and ‘non-serious cases’, and use inferencing techniques which are based on a set of medical rules provided by doctors to tell the computer which results are more valid than others. Biopsy results, for example, are more conclusive than Pap test results and may point to a pre-cancer stage that a Pap test did not reveal.”
Greatly expanded data pool
Working with the three hospitals, the ASSIST prototype platform now allows researchers access to thousands of patients’ records at the gynaecology and obstetrics departments of the three hospitals, including the results of annual tests on all women, not just those infected.
“We add extra functionality as we go along, but at least the doctors now have something to work with and evaluate,” says Mitkas.
The project recently hosted a conference where the platform was introduced to some of the leading cervical cancer specialists from around Europe, and they were so impressed that several of them have agreed to add their data to the ASSIST pool.
In the future, the work done on this project can be applied to other types of cancer, with just some adjustments being needed to the software to cope with different data sets, Mitkas suggests. And there is no reason why the platform cannot be used with other types of disease such as cardiovascular, he says.
“Further down the line, understanding the path to the disease and the factors that affect it will help individual doctors diagnose it earlier, prevent it by giving directions to their patients, and developing drugs or procedures that will cure the disease. But ASSIST is primarily a tool for medical researchers, and the results of their research will benefit all women,” Mitkas concludes.
Christian Nielsen | alfa
Novel chip-based gene expression tool analyzes RNA quickly and accurately
18.01.2018 | University of Illinois College of Engineering
Potentially life-saving health monitor technology designed by Sussex University physicists
10.01.2018 | University of Sussex
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
19.01.2018 | Life Sciences
19.01.2018 | Life Sciences
19.01.2018 | Physics and Astronomy